Press and media kit

What is PeptideAgent?

PeptideAgent is an independent editorial reference on peptides. It answers three questions about each peptide: what the evidence shows, whether it is legal to prescribe, compound, or use in tested sport, and how a person can access it through a licensed route. Every medical and legal claim cites a primary source, and the underlying dataset is free to reuse under CC BY 4.0 with attribution. PeptideAgent does not prescribe, dispense, or sell anything. Learn more at https://peptideagent.ai.

The author of record on every page is the organization. There are no personal bylines, and pages are editorially reviewed, not clinically reviewed; each page shows its review status. See the about page and the methodology for how evidence grades and statuses are assigned.

Citable statistics

These numbers are computed from the published dataset each time the site is built, so they always match the pages. Data as of 2026-09-27. Please cite the page the number comes from and link to it.

From the State of Peptides, 2026 Q3 report

• 57% of the 47 tracked peptides without an FDA approval have no randomized human trial behind them (27 peptides).
• 35 of 82 tracked peptides are FDA approved. The most common status among the rest is "unscheduled" (17 peptides).
• 51% of tracked peptides are prohibited in sport under the WADA list in force (42 of 82).
• 12 dated regulatory actions on tracked peptides in 2026 so far, 7 of them in the third quarter.
• 34 of 94 price channels in our cost data have a dated public source and a published price, covering 12 peptides.
• 12,083 to 98,396 sum of per-drug FAERS report counts for the FDA-approved GLP-1 and incretin peptides, 2016 versus 2025 (a report naming two of these drugs counts twice). Report counts are not incidence rates.
• 17 of 50 states allow asynchronous telehealth prescribing; 5 do not, and in 28 the state rules we checked do not address it.

Source: State of Peptides, 2026 Q3, with the method, caveats, and CSV downloads. The press release summarizes the headline findings.

Coverage of the reference

• 82 peptides with a full record
• 50 state legal and access guides
• 75 head-to-head comparisons
• 40 conditions mapped to peptides
• 62 dated regulatory events tracked

How to cite a page

• Cite the specific page, not the home page. Peptide, comparison, state, and report pages each carry a "Cite this page" block with an APA-style reference and an HTML link you can copy.
• Include the date. Pages change when rules or evidence change, so give the updated date shown on the page, and add the date you accessed it if your style requires one.
• Attribute the organization: "PeptideAgent", not an individual. For data reuse, the attribution line is: Data from PeptideAgent (https://peptideagent.ai), licensed under CC BY 4.0.
• For medical claims, cite the primary source we cite as well; each claim on a page links to its numbered source.
• Bulk data is on the data page and through the public API.

Logo files

Use the logo unaltered on a light background, with space around it at least the height of the mark. Do not imply endorsement of a product or service.

• Mark, SVG
• Wordmark, SVG